MYWOT
Child safety
Confidence
Trustworthiness
Confidence
MALICIOUS CONTENT INDICATORS
Norgine.com most likely does not offer any malicious content.
Secure connection support
HTTPS
Norgine.com provides SSL-encrypted connection.
ADULT CONTENT INDICATORS
Norgine.com most likely does not offer any adult content.
Audience
-
Gender
Men
46%
Women
54%
Popular pages
-
About us - Norgine
Norgine is a leading European specialist pharmaceutical company that has been bringing transformative products to patients for over a century. Our commitment to transforming people’s lives drives ever...
-
Our products - Norgine
Please note that the products mentioned below may not be available in all countries. Additionally, currently approved indications (uses) and presentations may differ between countries. To report an a...
-
Our story - Norgine
We are committed to building a future together by staying true to our heritage over the past 110 years of adapting, innovating and growing.
-
Norgine Announces Investment from Goldman Sachs Asset Management - Norgine
Norgine Announces Investment from Goldman Sachs Asset Management 26th May, 2022 – Today, Norgine Europe B.V. (“Norgine”, the “Company”), a leading European specialty pharmaceutical company, announced ...
-
Norgine Announces Closing of Investment from Goldman Sachs Asset Management - Norgine
15th December, 2022 – Today, Norgine Europe B.V. (“Norgine”, the “Company”), a leading European specialty pharmaceutical company, announced that the Private Equity business within Goldman Sachs Asset ...
-
AMAG Pharmaceuticals and Norgine B.V. enter into exclusive licensing agreement to commercialize
AMAG PHARMACEUTICALS AND NORGINE B.V. ENTER INTO EXCLUSIVE LICENSING AGREEMENT TO COMMERCIALIZE CIRAPARANTAG IN EUROPE, AUSTRALIA AND NEW ZEALAND Agreement provides AMAG with $30 million upfront p...